Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
15 Jul, 20:00
XSTU XSTU
133. 86
-0.4
-0.3%
- Market Cap
29.06 P/E Ratio
4.96% Div Yield
430 Volume
9.91 Eps
134.26
Previous Close
Day Range
133.52 134.44
Year Range
127.88 160.92
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 90 days

Summary

JNJ closed today lower at €133.86, a decrease of 0.3% from yesterday's close, completing a monthly increase of 3.1% or €4.02. Over the past 12 months, JNJ stock lost -4.41%.
JNJ pays dividends to its shareholders, with the most recent payment made on Jun 10, 2025. The next estimated payment will be in In 1 month on Sep 10, 2025 for a total of €1.3.
The last earnings report, released on 2 hours ago, missed the consensus estimates by -2.68%. On average, the company has fell short of earnings expectations by -0.89%, based on the last three reports. The next scheduled earnings report is due on Oct 14, 2025.
Johnson & Johnson has completed 6 stock splits, with the recent split occurring on Jun 13, 2001.
The company's stock is traded on 19 different exchanges and in various currencies, with the primary listing on NYSE (USD).

JNJ Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?

Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?

JNJ eyes Q2 growth with strong drug sales and new launches, but Stelara biosimilars and MedTech headwinds loom.

Zacks | 1 day ago
Johnson & Johnson: Buy JNJ Stock Ahead of Its Upcoming Earnings?

Johnson & Johnson: Buy JNJ Stock Ahead of Its Upcoming Earnings?

Johnson & Johnson (NYSE:JNJ) is set to report its earnings on Wednesday, July 16, 2025. For traders focused on events, analyzing historical stock behavior surrounding earnings reports can be an important strategy, possibly improving the odds in your favor.

Forbes | 1 day ago
Unveiling Johnson & Johnson (JNJ) Q2 Outlook: Wall Street Estimates for Key Metrics

Unveiling Johnson & Johnson (JNJ) Q2 Outlook: Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.

Zacks | 4 days ago

Johnson & Johnson Dividends

Johnson & Johnson logo
JNJ 1 month ago
Other
€1.11 Per Share
Johnson & Johnson logo
JNJ 4 months ago
Other
€1.06 Per Share
Johnson & Johnson logo
JNJ 7 months ago
Other
€1.06 Per Share
Johnson & Johnson logo
JNJ 10 months ago
Other
€1.06 Per Share
Johnson & Johnson logo
JNJ 20 May 2024
Other
€1.06 Per Share

Johnson & Johnson Earnings

14 Oct 2025 (In 3 months) Date
-
Cons. EPS
-
EPS
16 Jul 2025 16 Jul 2025 Date
2.68
Cons. EPS
-
EPS
14 Apr 2025 Date
-
Cons. EPS
-
EPS
21 Jan 2025 Date
-
Cons. EPS
-
EPS
15 Oct 2024 Date
-
Cons. EPS
-
EPS
Johnson & Johnson logo
JNJ 1 month ago
Other
€1.11 Per Share
Johnson & Johnson logo
JNJ 4 months ago
Other
€1.06 Per Share
Johnson & Johnson logo
JNJ 7 months ago
Other
€1.06 Per Share
Johnson & Johnson logo
JNJ 10 months ago
Other
€1.06 Per Share
Johnson & Johnson logo
JNJ 20 May 2024
Other
€1.06 Per Share
14 Oct 2025 (In 3 months) Date
-
Cons. EPS
-
EPS
16 Jul 2025 16 Jul 2025 Date
2.68
Cons. EPS
-
EPS
14 Apr 2025 Date
-
Cons. EPS
-
EPS
21 Jan 2025 Date
-
Cons. EPS
-
EPS
15 Oct 2024 Date
-
Cons. EPS
-
EPS

Johnson & Johnson (JNJ) FAQ

What is the stock price today?

The current price is €133.86.

On which exchange is it traded?

Johnson & Johnson is listed on NYSE.

What is its stock symbol?

The ticker symbol is JNJ.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 4.96%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Oct 14, 2025.

Has Johnson & Johnson ever had a stock split?

Johnson & Johnson had 6 splits and the recent split was on Jun 13, 2001.

Johnson & Johnson Profile

Drug Manufacturers - General Industry
Healthcare Sector
Joaquin Duato CEO
XSTU Exchange
US4781601046 ISIN
US Country
138,100 Employees
18 Feb 2025 Last Dividend
13 Jun 2001 Last Split
- IPO Date

Overview

Johnson & Johnson, a renowned entity in the healthcare sector, operates globally with a broad focus on research, development, manufacturing, and sales of healthcare products. The company is structured in multiple segments, primarily Innovative Medicine and MedTech, catering to a vast array of therapeutic areas and medical needs. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, illustrating a longstanding presence and commitment to healthcare innovation and advancement. Through its extensive product line and diversified service offerings, Johnson & Johnson reaches a wide audience, including retailers, wholesalers, distributors, hospitals, and healthcare professionals, providing prescription and non-prescription products alike.

Products and Services

The company's portfolio is divided into two main segments, each encompassing a variety of products and services designed to meet the complex demands of modern healthcare:

  • Innovative Medicine:

    This segment includes a range of products for different therapeutic areas. These encompass immunology (covering diseases like rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis), infectious diseases (including HIV/AIDS treatment), neuroscience (targeting mood disorders, neurodegenerative disorders, schizophrenia), oncology (focused on cancers such as prostate, lung, bladder, and hematologic malignancies), cardiovascular and metabolism (addressing conditions like thrombosis, diabetes, and macular degeneration), and pulmonary hypertension, specifically pulmonary arterial hypertension.

  • MedTech:

    This segment offers products and technologies across a range of medical fields. Interventional Solutions include electrophysiology products for heart rhythm disorders and technologies for severe coronary artery disease treatment. The neurovascular care line focuses on treating hemorrhagic and ischemic strokes. Orthopaedics products support treatments for hips, knees, trauma, spine, and sports injuries. The surgery portfolio covers advanced and general surgery technologies and solutions for breast aesthetics and ear, nose, and throat procedures. Additionally, MedTech offers visual health products like ACUVUE Brand contact lenses and TECNIS intraocular lenses for cataract surgery.

Contact Information

Address: One Johnson & Johnson Plaza
Phone: 732 524 0400